Boehringer Ingelheim and Ribo collaborate to develop therapeutics for liver diseases using RNA technology
Boehringer Ingelheim and Ribo have joined forces to create RNA-based therapeutics for the treatment of NASH/MASH.
Boehringer Ingelheim recently shared exciting news about their collaboration with Suzhou Ribo Life Science and Ribocure Pharmaceuticals. Together, they will be working on developing innovative RNA-based treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). The collaboration brings together Ribo's extensive knowledge in the field of small interfering RNA (siRNA) therapeutics and Boehringer Ingelheim's specialized focus on cardiovascular, renal, and metabolic diseases (CRM) market.
As part of the agreement, Ribo will receive an initial payment and may also be eligible for additional payments based on the success of the project. They will also receive royalties based on sales. The estimated value of the overall deal is expected to surpass $2 billion.
Ribo's RIBO-GalSTAR technology platform allows for the creation of RNA interference therapeutics that specifically target disease-causing genes in hepatocytes. This is achieved through the silencing of the messenger RNAs (mRNAs) of the genes. According to a company press release, this approach has the potential to revolutionize disease treatment by targeting previously unreachable drug targets.
“We look forward to working with the scientists from Ribo to develop new breakthrough medicines for patients with NASH,” said Søren Tullin, senior vice-president and global head of Cardiometabolic Diseases Research, Boehringer Ingelheim, in the press release. “This new partnership is part of our commitment to collaborate with peers worldwide to address the interconnected nature of CRM diseases. Our goal is to develop the next wave of innovative medicines that will lead to a holistic health gain for patients.”
“This collaboration represents a strong endorsement of the many years of investment and scientific discovery built into Ribo’s platform. We are very pleased about the opportunity to work with Boehringer Ingelheim to develop new solutions for people living with NASH,” said Zicai Liang, CEO, Ribo Life Sciences, in the release.
Source: Boehringer Ingelheim
